SAN DIEGO, May 2, 2008 (PRIME NEWSWIRE) -- Asphelia Pharmaceuticals, a privately-held, clinical-stage company focused on developing novel therapeutics for the treatment of a variety of immunological disorders, will be sponsoring a booth at this year's Digestive Disease Week (DDW) in San Diego. DDW is the world's largest gathering of physicians and researchers in the fields of gastroenterology, hepatology and endoscopy. This year's DDW will be held at the San Diego Convention Center from May 17 to May 22.
During this conference, Asphelia will feature a new video describing the immunomodulating effects of helminthes. Helminthes therapy and Trichuris suis ova specifically is a novel approach to treating many immunological diseases such as Crohn's Disease, Multiple Sclerosis, and allergic disorders. The technology is currently being assessed in several clinical studies being conducted globally.
About Asphelia Pharmaceuticals, Inc.
Asphelia Pharmaceuticals is a privately-held, clinical-stage company poised to change the course of immunological disorders. Asphelia's primary focus lies in its development of therapies targeting Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis), as well as other immunological and inflammatory disorders, including multiple sclerosis and asthma. Asphelia's lead compounds target the cause of Inflammatory Bowel Disease, not just its symptoms, in an effort to change the course of the diseases and allow patients new freedoms. Asphelia's immunotherapeutics seek to provide patients with safer, more effective and more convenient care.